Search | Médecins Sans Frontières Access Campaign

587 results found

Maria Atonio, 43-years-old farmer from Macomia, returns home after visiting MSF’s Clinic in Nanga to receive ART treatment and to have a medical appointment with MSF’s clinical officer to monitor her health.

Press release |

06 February 2024

Colombia takes significant next step to expand people’s access to affordable HIV treatment, and moves forward with compulsory license for HIV medicine dolutegravir

MSF welcomes Colombia taking a historic next step towards issuing first-ever compulsory license to increase access to more affordable generic versions of key HIV medicine dolutegravir

Tags HIV/AIDS HIV/AIDS Medicines Patent PoolWorld Health OrganizationViiV

Technical brief |

24 November 2023

Q&A: Access to cabotegravir long-acting (CAB-LA) for HIV pre-exposure prophylaxis (PrEP)

Q&A on access to HIV prevention drug CAB-LA

Tags HIV/AIDS HIV/AIDS cabotegravir ViiV

A clinician gathering antiretroviral medications for a patient at Maram Dispensary in Ndhiwa sub county, Homa Bay County, Kenya, 2021

Press release |

17 August 2023

MSF refuses to sign ViiV’s last-minute NDA for access to most-effective HIV prevention drug CAB-LA

MSF urges ViiV to withdraw problematic purchasing conditions hindering access to HIV prevention drug CAB-LA

Tags HIV/AIDS HIV/AIDS cabotegravir ViiV

Mr and Ms Kimboi, both of whom are living with HIV, picking up their medicines at the MSF Chakpikarong clinic, Thailand, 2019

Letter |

17 August 2023

Open letter to ViiV to improve access to HIV prevention drug CAB-LA

MSF letter to ViiV asking the company to withdraw problematic purchasing conditions for HIV prevention drug CAB-LA

Tags HIV/AIDS HIV/AIDS cabotegravir ViiV

Video |

17 August 2023

Testimonies for access to HIV prevention drug CAB-LA

CAB-LA is a game-changing HIV prevention medicine, but access to it is currently a challenge.

Tags HIV/AIDS HIV/AIDS cabotegravir

Letter |

13 July 2023

CSO letter supporting Resolution 881/23 by Colombia on issuing a compulsory license for HIV drug dolutegravir

MSF co-signed a CSO letter to Colombia welcoming a resolution on issuing a compulsory license for HIV drug dolutegravir

Tags HIV/AIDSIntellectual property and trade HIV/AIDS Colombia

Clinician preparing samples for a point-of-care CD4 testing machine, Homa Bay County teaching and referral hospital, Kenya

Press release |

11 May 2023

Access to point-of-care tests for people with advanced HIV under threat as diagnostics corporations to stop production

MSF warned that access to point-of-care CD4 tests for HIV are under threat because Abbott and Becton Dickinson have decided to stop production

Tags DiagnosticsHIV/AIDS HIV/AIDS World Health Organization

Vials of liposomal amphotericin B (L-AmB)

Press release |

03 May 2023

MSF calls on Gilead to finally fulfil access promise and make lifesaving drug for people with HIV available where needed

Gilead hikes price while liposomal amphotericin B (L-AmB) for treatment of HIV-related cryptococcal meningitis remains unavailable and unaffordable in countries where it’s most needed

Tags HIV/AIDS cryptococcal meningitis liposomal amphotericin B Gilead

Video |

03 May 2023

Access challenges for HIV opportunistic infection drug L-AmB

MSF Access Campaign answers three questions on the challenges accessing liposomal amphotericin B (L-AmB), a key drug for treating the deadly HIV opportunistic infection cryptococcal meningitis.

Tags HIV/AIDS cryptococcal meningitis

Geralda Saint Victor, nurse at Pran Men’m clinic, Port-au-Prince, Haiti, responding to the sexual and gender-based violence (SGBV) hotline. The MSF clinic provides medical and psychosocial care, including prophylaxis for HIV.

Press release |

30 March 2023

Pharmaceutical corporation ViiV must improve its failing access strategy for lifesaving HIV prevention drug

With affordable generics likely years away, ViiV must make information public on supply of long-acting cabotegravir and global distribution plan to ensure access for people in high HIV burden low- and middle-income countries

Tags HIV/AIDS HIV/AIDS cabotegravir ViiV

Technical brief |

02 February 2023

Agents of Change: Long-acting Formulations for Prevention and Treatment of HIV

Access to long-acting medicines will be key to meeting global HIV prevention and treatment targets.

Tags HIV/AIDS HIV/AIDS cabotegravir

Aisha Diabate 30 years (background) arrived at MSF’s specialised AIDS unit in Donka University Hospital with the husband of her sister who is a doctor from Coleah health centre in Conakry.

Press release |

29 November 2022

Pharmaceutical corporation ViiV must make ground-breaking HIV prevention injection affordable and available

MSF calls on ViiV to urgently dismantle barriers to access for long-acting cabotegravir

Tags HIV/AIDS HIV/AIDS cabotegravir World Health OrganizationViiV

Technical brief |

13 September 2022

Africa-South Korea Roundtable: Working Together on Local Production of Diagnostics

The challenges and opportunities offered by increasing local production of diagnostic tests in the African region

Tags Diagnostics coronavirusHIV/AIDSmalarianeglected diseasestuberculosis

Research article |

29 August 2022

Clinical Infectious Diseases: Access to medicines for treating people with cryptococcal meningitis

MSF, Unitaid and WHO authors discuss the need to improve access to liposomal amphotericin B (L-AmB) for the treatment of HIV-associated cryptococcal meningitis.

Tags HIV/AIDS cryptococcal meningitis liposomal amphotericin B UNITAIDWorld Health Organization

Statement |

23 August 2022

Principles for Access to Multi-disease Molecular Diagnostics

Following a roundtable discussion with funders, governments and other procurers, a set of principles has been developed to enable better outcomes to negotiations with diagnostic manufacturers.

Tags Diagnostics coronavirusdrug-resistant TBhepatitis CHIV/AIDStuberculosis GeneXpert Treatment Action CampaignCepheid

Infographic

Cabotegravir for PrEP

In 2020, around 1.5 million people were newly infected with HIV. Global targets endorsed at the World Health Assembly 2022 aim to reduce new HIV infections from 1.5 million to under 370,000 by 2025 and under 335,000 by 2030. In order ...

Tags HIV/AIDS HIV/AIDS cabotegravir

Issue brief |

25 July 2022

Cabotegravir: What are we waiting for?

Tags HIV/AIDS HIV/AIDS cabotegravir Medicines Patent PoolWorld Health Assembly

Letter |

19 July 2022

CSO letter to ViiV calling for access to HIV PrEP drug CAB-LA

CSO letter to ViiV on access to HIV PrEP drug cabotegravir

Tags HIV/AIDS HIV/AIDS

Cryptococcal disease facts and barriers to access

Infographic

Cryptococcal meningitis

Cryptococcal meningitis is an opportunistic fungal infection, which is the number two killer of people living with HIV/AIDS after tuberculosis. With timely and effective diagnosis and treatment, people living with HIV/AIDS can survive ...

Tags HIV/AIDS cryptococcal meningitis liposomal amphotericin B

Press release |

20 April 2022

MSF responds to new simplified WHO treatment guidelines for cryptococcal meningitis, the number two killer of people living with HIV/AIDS

MSF urges all countries to adopt the guidelines and outlines the actions needed to make the WHO-recommended treatment accessible to people who need it

Tags HIV/AIDS cryptococcal meningitis liposomal amphotericin B World Health Organization

Date

Primary topics

Types of content

Products

Diseases

General Terms

Geography

Campaigns

Institutions & Events

Report series

Miscellaneous

Colombia takes significant next step to expand people’s access to affordable HIV treatment, and moves forward with compulsory license for HIV medicine dolutegravir

Q&A: Access to cabotegravir long-acting (CAB-LA) for HIV pre-exposure prophylaxis (PrEP)

MSF refuses to sign ViiV’s last-minute NDA for access to most-effective HIV prevention drug CAB-LA

Open letter to ViiV to improve access to HIV prevention drug CAB-LA

Testimonies for access to HIV prevention drug CAB-LA

CSO letter supporting Resolution 881/23 by Colombia on issuing a compulsory license for HIV drug dolutegravir

Access to point-of-care tests for people with advanced HIV under threat as diagnostics corporations to stop production

MSF calls on Gilead to finally fulfil access promise and make lifesaving drug for people with HIV available where needed

Access challenges for HIV opportunistic infection drug L-AmB

Pharmaceutical corporation ViiV must improve its failing access strategy for lifesaving HIV prevention drug

Agents of Change: Long-acting Formulations for Prevention and Treatment of HIV

Pharmaceutical corporation ViiV must make ground-breaking HIV prevention injection affordable and available

Africa-South Korea Roundtable: Working Together on Local Production of Diagnostics

Clinical Infectious Diseases: Access to medicines for treating people with cryptococcal meningitis

Principles for Access to Multi-disease Molecular Diagnostics

Cabotegravir for PrEP

Cabotegravir: What are we waiting for?

CSO letter to ViiV calling for access to HIV PrEP drug CAB-LA

Cryptococcal meningitis

MSF responds to new simplified WHO treatment guidelines for cryptococcal meningitis, the number two killer of people living with HIV/AIDS